Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Gains from Sales and Divestitures (2016 - 2025)

Achieve Life Sciences (ACHV) has disclosed Gains from Sales and Divestitures for 13 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 1374.05% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 1374.05% year-over-year, with the annual reading at $1.7 million for FY2025, 1374.05% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $1.7 million at Achieve Life Sciences, roughly flat from $1.7 million in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.7 million in Q3 2025, with the low at $231.0 in Q3 2021.
  • Average Gains from Sales and Divestitures over 5 years is $321077.1, with a median of $113125.0 recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures soared 11425.97% in 2022, then decreased 19.05% in 2024.
  • Achieve Life Sciences' Gains from Sales and Divestitures stood at $231.0 in 2021, then soared by 11425.97% to $26625.0 in 2022, then skyrocketed by 424.88% to $139750.0 in 2023, then fell by 19.05% to $113125.0 in 2024, then skyrocketed by 1374.05% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ACHV's Gains from Sales and Divestitures are $1.7 million (Q4 2025), $1.7 million (Q3 2025), and $113125.0 (Q4 2024).